<DOC>
	<DOCNO>NCT02555800</DOCNO>
	<brief_summary>The aim study compare efficacy intralesional bevacizumab , monoclonal antibody vascular endothelial growth factor , versus antiviral drug cidofovir patient recurrent respiratory papillomatosis .</brief_summary>
	<brief_title>Bevacizumab Versus Cidofovir Treatment Recurrent Respiratory Papillomatosis</brief_title>
	<detailed_description>The investigator design randomize , double-blind , placebo-controlled study . Children adult randomize receive either 3 dosis intralesional bevacizumab , cidofovir saline solution . Primary endpoint assessment change annual surgery rate Derkay papilloma severity grade scale ; secondary endpoint change Voice Handicap Index safety .</detailed_description>
	<mesh_term>Papilloma</mesh_term>
	<mesh_term>Respiratory Tract Infections</mesh_term>
	<mesh_term>Papillomavirus Infections</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Cidofovir</mesh_term>
	<criteria>Patients diagnose recurrent respiratory papillomatosis proven biopsy . Patients 2 previous surgery papillomatosis Patients heart renal disease Patients receive another adjuvant therapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Laryngeal papillomatosis</keyword>
	<keyword>Cidofovir</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Recurrent respiratory papillomatosis</keyword>
</DOC>